(:SELB)

Jan 08, 2024 07:10 am ET
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today highlighted its recent progress and outlined 2024 strategic priorities across its...
Jan 08, 2024 07:00 am ET
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company”) a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08...
Nov 16, 2023 10:42 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Nov 13, 2023 08:05 am ET
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases. In connection with the...
Nov 11, 2023 08:26 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Selecta Biosciences, Inc. (NASDAQ: SELB) (“Selecta”) on behalf of the company’s investors. Since February 2023, shares of Selecta’s common stock have declined in value from a trading price of...
Nov 03, 2023 12:27 am ET
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Selecta Biosciences, Inc.; Urges Selecta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Selecta’s board of directors (the “Board”) has violated...
Oct 31, 2023 04:03 pm ET
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an...
Aug 17, 2023 07:00 am ET
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second...
May 31, 2023 07:00 am ET
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced the presentation of positive data...
May 04, 2023 07:30 am ET
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first...
Apr 28, 2023 04:05 pm ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a conference...
Mar 21, 2023 08:34 am ET
Thinking about buying stock in Selecta Biosciences, On Holding AG, eMagin, Harmonic, or Canadian Solar?
NEW YORK, March 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SELB, ONON, EMAN, HLIT, and CSIQ.
Mar 21, 2023 03:30 am ET
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized clinical trials to determine safety and efficacy of two different dose levels of SEL-212 in...
Mar 02, 2023 07:30 am ET
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
IND enabling studies expected to commence in 2023 for interleukin-2 (IL-2) candidate to be studied in combination with ImmTOR™, as well as IgA protease candidate for the treatment of IgA Nephropathy - - As of December 31, 2022, Selecta had...
Feb 23, 2023 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference...
Feb 07, 2023 08:00 am ET
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company’s Management will...
Jan 09, 2023 08:00 am ET
Selecta Biosciences Provides Business Update and Outlook for 2023
WATERTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies,...
Jan 09, 2023 06:30 am ET
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease
Dec 14, 2022 08:00 am ET
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced the selection of a next generation...
Nov 28, 2022 08:00 am ET
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of...
Nov 07, 2022 08:00 am ET
Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies...
Nov 03, 2022 08:00 am ET
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies...
Oct 27, 2022 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies...
Oct 11, 2022 08:00 am ET
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, today announced three upcoming...
Sep 29, 2022 08:00 am ET
Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies...
Sep 12, 2022 08:00 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Sep 06, 2022 08:00 am ET
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Aug 04, 2022 07:30 am ET
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies...
Aug 01, 2022 08:00 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Jul 28, 2022 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Jul 14, 2022 08:35 am ET
Thinking about buying stock in Selecta Biosciences, Adial Pharmaceuticals, Exela Technologies, Theravance Biopharma, or Organogenesis?
NEW YORK, July 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SELB, ADIL, XELA, TBPH, and ORGO.
Jul 06, 2022 08:00 am ET
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Jun 29, 2022 07:00 am ET
Surface Oncology Appoints Carsten Brunn to Board of Directors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s board of directors. Dr....
Jun 13, 2022 07:30 am ET
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
Jun 09, 2022 09:31 am ET
Thinking about buying stock in Applied UV, Nio, Wejo Group, Helius Medical Technologies, or Selecta Biosciences?
NEW YORK, June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, NIO, WEJO, HSDT, and SELB.
May 17, 2022 08:00 am ET
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
May 05, 2022 07:30 am ET
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to...
May 02, 2022 04:30 pm ET
Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, power gene therapies and mitigate unwanted immune responses to...
Apr 28, 2022 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a...
Apr 06, 2022 06:56 pm ET
Selecta Biosciences Announces $38.7 Million Underwritten Offering
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its...
Apr 04, 2022 08:00 am ET
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Mar 10, 2022 08:00 am ET
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune tolerance (ImmTOR-IL)- -Further validated and expanded the ImmTOR precision immune tolerance...
Mar 03, 2022 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR®, to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today...
Feb 09, 2022 08:00 am ET
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Jan 10, 2022 07:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the...
Jan 10, 2022 06:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ --  Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids. This partnership leverages the unique platforms of both companies as they seek to develop next-generation viral capsids with improved
Jan 05, 2022 08:00 am ET
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Dec 29, 2021 08:00 am ET
Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Dec 20, 2021 08:31 am ET
Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC.
Dec 14, 2021 07:30 am ET
Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences?
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB.
Dec 01, 2021 08:00 am ET
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI), today announced the completion of enrollment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development program of...
Nov 24, 2021 04:15 pm ET
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that the U.S. Food and Drug...
Nov 11, 2021 08:00 am ET
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Nov 09, 2021 08:00 am ET
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the...
Nov 08, 2021 08:12 am ET
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced top-line results from a joint Selecta and AskBio...
Nov 05, 2021 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a...
Oct 26, 2021 08:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the...
Oct 26, 2021 08:00 am ET
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
BOSTON and WATERTOWN, Mass., Oct. 26, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases. This partnership leverages the unique platforms of both companies.
Oct 21, 2021 08:00 am ET
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Genovis (GENO), an enzyme technology...
Oct 20, 2021 08:00 am ET
Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Oct 13, 2021 08:00 am ET
Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced it will be presenting...
Oct 04, 2021 08:00 am ET
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it has entered into a...
Sep 21, 2021 08:00 am ET
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management...
Sep 20, 2021 08:00 am ET
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin...
Sep 09, 2021 08:00 am ET
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Sep 08, 2021 08:00 am ET
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Cyrus Biotechnology, Inc. a leading...
Aug 12, 2021 08:00 am ET
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the...
Aug 05, 2021 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a...
Aug 02, 2021 08:00 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Jul 26, 2021 08:00 am ET
Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Aci
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment...
Jul 08, 2021 08:00 am ET
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Jun 24, 2021 08:00 am ET
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Nishan...
Jun 16, 2021 08:00 am ET
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Jun 14, 2021 08:00 am ET
Selecta Biosciences to Participate at the LifeSci Partners Genetic Medicines Summit 2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Jun 01, 2021 08:00 am ET
Selecta Biosciences Announces Frontiers in Immunology Publication Showcasing the Enhanced Hepatic Tolerogenic Potential of ImmTOR™
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the...
May 25, 2021 08:00 am ET
Selecta Biosciences to Participate at the Jefferies Virtual Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
May 13, 2021 08:00 am ET
 Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the...
May 06, 2021 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host...
Apr 29, 2021 04:15 pm ET
Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming...
Apr 29, 2021 08:30 am ET
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced an update to the companies’ collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR™ for the treatment of methylmalonic acidemia...
Apr 05, 2021 08:00 am ET
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Mar 11, 2021 08:00 am ET
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported recent business highlights...
Mar 04, 2021 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host...
Mar 01, 2021 08:00 am ET
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Feb 25, 2021 07:30 am ET
Thinking about buying stock in GameStop, AMC Entertainment, Dynatronics Corp, Selecta Biosciences, or vTv Therapeutics?
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, DYNT, SELB, and VTVT.
Feb 24, 2021 04:15 pm ET
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the...
Feb 17, 2021 08:00 am ET
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced the initiation of a Phase 1 dose-escalation trial of SEL-399, an...
Feb 17, 2021 07:00 am ET
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
WATERTOWN, Mass., and Research Triangle Park, N.C., Feb. 17, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced the initiation of a Phase 1 dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) containing no DNA combined with ImmTOR™. The trial aims to determine the optimal dose of ImmTOR to mitigate the formation of antibodies to AAV8 capsids used in gene therapies.
Feb 16, 2021 08:00 am ET
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Feb 03, 2021 07:30 am ET
Thinking about buying stock in Sundial Growers, Sellas Life Sciences, Selecta Biosciences, Outlook Therapeutics, or Zynerba Pharmaceuticals?
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, SLS, SELB, OTLK, and ZYNE.
Jan 26, 2021 07:30 am ET
Thinking about buying stock in Edesa Biotech, Phunware, Vertex Energy, electroCore, or Selecta Biosciences?
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, PHUN, VTNR, ECOR, and SELB.
Jan 06, 2021 08:00 am ET
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced preclinical data...
Jan 04, 2021 08:00 am ET
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Nov 19, 2020 08:00 am ET
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for...
Nov 19, 2020 08:00 am ET
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for...
Nov 10, 2020 08:00 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief...
Nov 05, 2020 07:30 am ET
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced financial results for the...
Oct 29, 2020 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a...
Oct 26, 2020 08:30 am ET
Thinking about buying stock in Dunkin Brands, Selecta Biosciences, Nokia, Pinterest, or Snap?
NEW YORK, Oct. 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DNKN, SELB, NOK, PINS, and SNAP.
Oct 21, 2020 09:31 am ET
Thinking about buying stock in Staffing 360 Solutions, IBM, Selecta Biosciences, 3M, or Aileron Therapeutics?
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, IBM, SELB, MMM, and ALRN.
Oct 20, 2020 08:00 am ET
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated...
Oct 20, 2020 08:00 am ET
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated...
Oct 16, 2020 09:31 am ET
Thinking about buying stock in Rewalk Robotics, Selecta Biosciences, Aphria, Plug Power, or Aslan Pharmaceuticals?
NEW YORK, Oct. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RWLK, SELB, APHA, PLUG, and ASLN.
Oct 08, 2020 04:05 pm ET
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment
Selecta Biosciences, Inc. (NASDAQ: SELB) and IGAN Biosciences, Inc. today announced that they have entered into a Research License and Option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A...
Sep 30, 2020 04:15 pm ET
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout
Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline data for the Phase 2 COMPARE trial comparing the efficacy of SEL-212, a combination of Selecta’s ImmTOR™ immune tolerance...
Sep 24, 2020 04:16 pm ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that Selecta’s Chief Executive Officer,...
Sep 23, 2020 07:00 am ET
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient...
Sep 08, 2020 08:00 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
Sep 01, 2020 08:00 am ET
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that it has entered into a debt...
Aug 06, 2020 07:30 am ET
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, today reported financial results for the second quarter...
Aug 03, 2020 04:05 pm ET
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Peter G. Traber, MD,...
Aug 03, 2020 08:15 am ET
Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
Jul 30, 2020 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a...
Jul 28, 2020 06:00 am ET
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta Biosciences, Inc. (Nasdaq: SELB) for SEL-212, entered into as earlier announced on June 11, 2020, became effective on July 28,...
Jun 18, 2020 08:30 am ET
Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that they have entered into a Research License and Option agreement granting Sarepta an...
Jun 18, 2020 08:30 am ET
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that they have entered into a Research License and Option agreement granting Sarepta an...
Jun 15, 2020 08:00 am ET
Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
Jun 11, 2020 05:15 pm ET
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212 is a combination of...
May 26, 2020 08:00 am ET
Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
May 07, 2020 07:30 am ET
Selecta Biosciences Reports First Quarter 2020 Financial Results
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for the first quarter...
May 06, 2020 12:04 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Selecta Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, May 6, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Selecta Biosciences, Inc. (NASDAQ: SELB).
May 05, 2020 08:00 am ET
Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
Apr 30, 2020 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call...
Apr 28, 2020 08:00 am ET
Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Dr. Goran Ando to its...
Apr 07, 2020 08:00 am ET
Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer,...
Mar 12, 2020 08:00 am ET
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for the fourth quarter...
Mar 05, 2020 08:00 am ET
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a...
Feb 18, 2020 08:00 am ET
Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief...
Dec 19, 2019 08:25 am ET
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of the agreement, AskBio has exercised its option to exclusively...
Dec 19, 2019 08:25 am ET
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of the agreement, AskBio has exercised its option to exclusively...
Dec 19, 2019 08:15 am ET
Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the completion of patient...
Dec 19, 2019 08:00 am ET
Selecta Biosciences Announces $70 Million Private Placement
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it has entered into...
Nov 21, 2019 08:00 am ET
Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Carrie S....
Nov 12, 2019 08:00 am ET
Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief...
Nov 11, 2019 09:00 am ET
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced new data from their Phase 2...
Nov 08, 2019 08:00 am ET
Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today reported financial results for the...
Nov 01, 2019 08:09 am ET
Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its...
Oct 24, 2019 08:00 am ET
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that data from the company’s...
Oct 23, 2019 10:48 am ET
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its...
Sep 25, 2019 08:00 am ET
Selecta Biosciences to Participate in Two Investor Conferences in October
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief...
Sep 04, 2019 08:00 am ET
Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Brad Dahms...
Sep 03, 2019 08:07 am ET
Selecta Biosciences to Present at the Janney Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief...
Aug 08, 2019 08:00 am ET
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today reported financial results for the...
Aug 07, 2019 07:00 am ET
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a strategic partnership to jointly develop, manufacture and commercialize targeted therapeutics for life-changing, next-generation...
Aug 01, 2019 08:00 am ET
Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its...
Jul 31, 2019 08:00 am ET
Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that CEO and President...
Jul 15, 2019 08:00 am ET
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Alison...
Jun 20, 2019 04:05 pm ET
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Scott D....
Jun 12, 2019 08:00 am ET
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, will present full data from the company’s...
May 30, 2019 08:00 am ET
Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced that CEO and...
May 09, 2019 08:00 am ET
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today reported financial results for the first...
May 02, 2019 08:00 am ET
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Apr 16, 2019 04:05 pm ET
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced that five presentations of new...
Apr 11, 2019 07:55 am ET
Research Report Identifies Chimerix, Evolent Health, ABIOMED, Syndax Pharmaceuticals, Independence Realty Trust, and Selecta Biosciences with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chimerix, Inc. (NASDAQ:CMRX), Evolent Health, Inc (NYSE:EVH), ABIOMED,...
Apr 02, 2019 08:00 am ET
Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Mar 29, 2019 08:00 am ET
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today announced the initiation of a six month...
Mar 26, 2019 04:05 pm ET
Selecta Biosciences Announces New Employment Inducement Grant
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Elona Kogan, J.D. commenced her...
Mar 15, 2019 08:00 am ET
Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, today reported financial results for the...
Mar 08, 2019 08:00 am ET
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Mar 06, 2019 04:01 pm ET
Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Jan 23, 2019 09:19 am ET
Selecta Biosciences Announces Pricing of Public Offering of Common Stock
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Jan 22, 2019 04:01 pm ET
Selecta Biosciences Announces Proposed Public Offering of Common Stock
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced...
Jan 03, 2019 04:11 pm ET
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP-Rapamycin), today provided updates on its...
Dec 03, 2018 08:00 am ET
Selecta Biosciences Announces New Employment Inducement Grants
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Carsten Brunn, Ph.D. commenced his...
Nov 19, 2018 09:00 am ET
Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Command Center Inc. (NASDAQ:CCNI), Neurotrope, Inc. (NASDAQ:NTRP),...
Nov 08, 2018 08:00 am ET
Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today reported financial results for the third quarter ended...
Nov 06, 2018 08:00 am ET
Selecta Biosciences to Present at the Stifel Healthcare Conference 2018
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy,...
Nov 01, 2018 08:00 am ET
Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that it plans to issue its third quarter...
Oct 23, 2018 07:05 am ET
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today presented new interim Phase 2 data from patients...
Oct 16, 2018 08:00 am ET
Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that new data from the ongoing Phase 2 study...
Oct 05, 2018 10:01 am ET
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
Généthon, a non-profit R organization founded by the AFM-Téléthon, and Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company, today announced that Nature Communications has published their jointly authored paper...
Sep 27, 2018 07:30 am ET
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, announced today that Carsten Brunn, Ph.D., has been...
Sep 25, 2018 08:00 am ET
Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy,...
Sep 20, 2018 08:00 am ET
Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CSO Takashi Kei Kishimoto, Ph.D., will...
Sep 10, 2018 08:00 am ET
Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy John...
Aug 31, 2018 08:00 am ET
Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Chief Scientific Officer Takashi Kei...
Aug 08, 2018 08:00 am ET
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today reported financial results for the second quarter...
Aug 02, 2018 08:00 am ET
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy John...
Aug 01, 2018 08:00 am ET
Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call
Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that it plans to issue its second quarter...
Jun 15, 2018 05:30 am ET
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today presented expanded data from patients receiving up to...
Jun 08, 2018 08:00 am ET
Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced a poster presentation entitled SEL-212:...
May 30, 2018 08:00 am ET
Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018
Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy John...
May 09, 2018 08:00 am ET
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today reported financial results for the first quarter ended...
May 02, 2018 08:00 am ET
Selecta Biosciences Announces Date of First Quarter 2018 Financial Results Conference Call
WATERTOWN, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immunogenicity, today announced that it plans to issue its first...
May 01, 2018 08:00 am ET
Selecta Biosciences to Present at Upcoming Investor Conferences
WATERTOWN, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating  unwanted immunogenicity, today announced that members of the Selecta management team...
Apr 10, 2018 08:00 am ET
Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress
WATERTOWN, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immunogenicity, today presented new data from patients receiving SEL-212 for...
Apr 03, 2018 08:00 am ET
Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018
WATERTOWN, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced a poster presentation of the Phase...
Mar 20, 2018 04:01 pm ET
Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018
WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that CEO and President Werner Cautreels,...
Mar 15, 2018 08:00 am ET
Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today reported financial results for the fourth quarter...
Mar 12, 2018 08:00 am ET
Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
WATERTOWN, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that the first patient has been...
Mar 08, 2018 08:00 am ET
Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018
WATERTOWN, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it will report its fourth...
Jan 02, 2018 08:05 am ET
Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy
Phase 1 Trial of SEL-403 (SVP-Rapamycin in Combination with LMB-100) in Mesothelioma Expected to be Underway in Q1 2018
Jan 02, 2018 08:00 am ET
Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that President and CEO Werner Cautreels,...
Nov 13, 2017 08:00 am ET
Selecta Biosciences to Webcast Investor Conference Presentations This Week
WATERTOWN, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that CEO and Chairman Werner Cautreels,...
Nov 07, 2017 07:30 am ET
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today reported financial results for the third quarter...
Oct 05, 2017 08:00 am ET
Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
WATERTOWN, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced the following upcoming clinical presentations:...
Aug 11, 2017 07:00 am ET
Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
Positive Data from Ongoing Phase 2 Study of SEL-212 Reported at Clinical Meetings in June 2017Further Preclinical Data Confirm Immune Tolerance Platform’s Broad PotentialRecent Financing Extends Cash Runway Into 2019Company to Host Conference Call Today at 8:30 a.m. ET WATERTOWN, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today reported financial results for the second quarter ended June 30, 2017 and provided ...
Jun 26, 2017 08:00 am ET
Selecta Biosciences Announces $50 Million Private Placement
WATERTOWN, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has entered into definitive agreements to sell securities in a private placement that is expected to result in gross proceeds to the company of $50 million, before deducting placement agent and other offering expenses. ...
May 11, 2017 04:05 pm ET
Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update
On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017Licensed LMB-100, a Clinical-Stage Candidate for Mesothelioma and Pancreatic Cancer, from the National Cancer Institute (NCI) Obtained Synthetic Transgene License for MMA Gene Therapy ProgramInitiated Nicotine Vaccine Phase 1 Trial for Smoking Cessation and Relapse Prevention with Funding Primarily from the National Institutes of Health (NIH)Company to Host Conference Call Today at 5:00 p.m. ET WATERTOWN, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharma...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.